Holen Sie sich die Stockscreener-App
4.05
1.94%
-0.08
Schlusskurs vom Vortag:
$4.13
Offen:
$4.08
24-Stunden-Volumen:
372.43K
Relative Volume:
0.45
Marktkapitalisierung:
$78.33M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-84.53M
KGV:
-0.6965
EPS:
-5.8145
Netto-Cashflow:
$-73.65M
1W Leistung:
-10.40%
1M Leistung:
-47.67%
6M Leistung:
-60.37%
1J Leistung:
-76.70%
1-Tages-Spanne:
$3.93
$4.08
1-Wochen-Bereich:
$3.93
$4.68
52-Wochen-Spanne:
$3.93
$18.11
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
4.05 | 78.33M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-29 | Eingeleitet | Guggenheim | Buy |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
A throat cancer trial doses its first patient as Corbus (CRBP) reports CRB-701 response data. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38 - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RA Capital Management Acquires 1,914,788 Shares of Corbus Pharmaceuticals (CRBP) - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Four parties report the same Corbus (CRBP) stake, held directly by one fund. - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
EBITDA of Corbus Pharmaceuticals Holdings Inc – HAN:3371 - TradingView
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - finance.yahoo.com
About 14,000 U.S. patients may qualify yearly for another throat cancer treatment. Corbus doses its first trial patient. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why Is Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Into Focus? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Cannabis Stocks Stock Everyone's About to Talk About? - Kalkine Media
(CRBP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings (Nasdaq:CRBP)Stock Analysis - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP - Finviz
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss TherapySlideshow (NASDAQ:CRBP) 2026-09-17 - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers - webull.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Saxena Nishant C | Chief Business Officer |
Aug 11 '26 |
Buy |
9.63 |
2,600 |
25,036 |
77,900 |
| Stifel, Nicolaus & Company, In | Officer |
Aug 07 '26 |
Proposed Sale |
10.08 |
17,000 |
171,396 |
0 |
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
| Stifel, Nicolaus & Company, In | Officer |
Aug 07 '26 |
Proposed Sale |
10.08 |
12,000 |
120,971 |
0 |
| Smethurst Dominic | Officer |
Jul 27 '26 |
Proposed Sale |
9.20 |
23,025 |
211,818 |
0 |
| Kung Winston | Director |
Jun 10 '26 |
Sale |
7.91 |
2,026 |
16,033 |
12,140 |
| Altmeyer Anne | Director |
Jun 10 '26 |
Sale |
7.91 |
2,412 |
19,088 |
7,579 |
| Jenkins John Kenneth | Director |
Jun 10 '26 |
Sale |
7.91 |
4,800 |
37,986 |
3,833 |
| Saxena Nishant C | Chief Business Officer |
Jun 03 '26 |
Buy |
7.58 |
9,000 |
68,220 |
75,300 |
3.09%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):